Achieve Life Sciences (NASDAQ: ACHV) reported Q3 EPS of ($1.14), $0.17 better than the analyst estimate of ($1.31). Revenue for the quarter came in at $0 , versus $0 reported last year.

As of September 30, 2020, the company\'s cash, cash equivalents, and restricted cash was $22.4 million. Total operating expenses for the three and nine months ended September 30, 2020 were $3.8 million and $10.0 million, respectively. Total net loss for the three and nine months ended September 30, 2020 was $3.8 million and $10.0 million, respectively.

For earnings history and earnings-related data on Achieve Life Sciences (ACHV) click here.